Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multicenter Study to Analyze the Predictive Value of Fusion Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Metastatic CRPC no Previously Treated With Chemotherapy

NCT02288936 is registered in ClinicalTrials.gov with Spanish Oncology Genito-Urinary Group as lead sponsor.

NCT NCT02288936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02288936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multicenter Study to Analyze the Predictive Value of Fusion Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Metastatic CRPC no Previously Treated With Chemotherapy
Lead sponsor
Spanish Oncology Genito-Urinary Group
Phase
Phase 2
Overall status
Completed
Start date
February 5, 2015
Completion date
July 22, 2019
Enrollment
98 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hormone-refractory prostate cancer